Xavier Valencia
Head of IBD Franchise Enveda Biosciences Inc.
Xavier brings an exceptional track record across multiple therapeutic areas and modalities. Most recently at Ventus Therapeutics, he led the development of a brain-penetrant NLRP3 inhibitor and a first-in-class cGAS inhibitor. His career spans leadership roles in gene & cell therapy (Tr1X), small molecules (Strongbridge Biopharma), and biologics (Boston Pharmaceuticals)—driving programs all the way from IND submission through to BLA/NDA filings
Seminars
Thursday 2nd April 2026
Roundtable Discussion: Delivering Faster & More Reliable IBD Trials by Redefining Recruitment Strategies
2:00 pm
- Explore innovative recruitment and retention strategies that have successfully reduced trial delays
- Discuss methods to minimize placebo variability and enhance statistical confidence. How are different teams approaching this challenge?
- Share experiences using real-world data and predictive tools to identify ideal candidates, what impact has this had on response rates and trial costs?
